Remdesivir Market Growth | Size, Trends, Forecast (2021-2030)

Upcoming

2023

Remdesivir Market

by Dosage (2.5MG, 5MG, 100MG, 200MG), by Form (Lyophilized Powder, Concentrated Solution), by Application (Ebola, SARS-COV, MERS-COV) and by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Medical Devices & Supplies	Report Code: A13229	Nov 2023 \| Pages: NA
Tables: NA	Charts: NA	Formats*: Single User License, Five User License & Enterprise User License Data Pack Excel License It comes with the additional cost of $2500.00 contact sales.

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Remdesivir Market

Request Now !

Remdesivir Market Outlook 2030

Remdesivir is a broad spectrum anti-viral medication which was firstly developed by Gilead Sciences. It is administered through injection into the vein. Remdesivir is a prodrug of nucleotide. In COVID-19 pandemic remdesivir was authorized for emergency treatment of COVID-19 around the 50 countries as per the recommendation of WHO in November 2020. Originally remdesiver is used in treatment of hepatitis C, Ebola virus, and Marburg virus infections. Moreover, remdesivir can be used in treatment of respiratory infections, feline infections, and arenaviruses. Nausea, liver infection, low blood pressure, and vomiting are common adverse effects of remdesivir.

COVID-19 Impact Analysis

COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the remdesivir market.

Top Impacting Factors

Rise in cases of viral infections, surge in unhygienic practices in rural areas, increase in demand to overcome from viral infections, surge in cases of COVID-19 across the globe, increase in geriatric population, and rise in hospital acquired infections are the key factors that drive the growth of the remdesivir market.
In addition, rise in investment in health care sector, occurrence of various pandemic diseases such as Ebola and COVID-19, government initiatives to promote manufacturing of remdesivir, emerging modern healthcare technologies in developing countries, R & D activities to improve quality of remdesivir, launch of novel drugs, and joint ventures, collaboration, and agreements between key market players can boost the growth of the remdesivir market.
However, shortage of remdesivir supply and availability of substitutes can hinder the growth of the market.
Contrarily, favourable reimbursement policies by governments and fast track regulatory approvals are expected to offer lucrative opportunities for the expansion of the market.

Market Trends

New Product Launches to Flourish the Market

In 2020, Jubilant Life Sciences announced launch of remdesivir for injection 100mg vial under the brand name JUBI-R. This injection can be used in treatment of COVID-19.

In 2020, Mylan announced commercial launch of remedesivir for injection under the brand name DESREMTM in India. This is a licensed drug for treatment of COVID-19 patients.

In 2020, Zydus Cadila announced launch of remdesivir lyophilised injection 100mg/vial. This injection can be used for patients suffering from SARS-CoV2.

Key Benefits of the Report

This study presents the analytical depiction of remdesivir market industry along with the current trends and future estimations to determine the imminent investment pockets.
The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the remdesivir market share.
The current market is quantitatively analyzed to highlight the remdesivir market growth scenario.
Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.

Questions Answered in the Remdesivir Market Report

Which are the leading players active in the remdesivir market?
What are the current trends that will influence the market in the next few years?
What are the driving factors, restraints, and opportunities of the market?
What future projections would help in taking further strategic steps?
What is "remdesivir"?
What is "remdesivir" market prediction in the future?
Who are the leading global players in the "remdesivir" market?
What are the current trends and predicted trends?
What are the key benefits of the "remdesivir" market report?

Remdesivir Market Report Highlights

Aspects	Details
By Dosage	2.5MG 5MG 100MG 200MG
By Form	Lyophilized Powder Concentrated Solution
By Application	Ebola SARS-COV MERS-COV
By Distribution Channel	Hospital Pharmacy Retail Pharmacy Online Pharmacy
By Region	North America (U.S., Canada, Mexico) Europe (France, Germany, Italy, Spain, UK, Rest of Europe) Asia-Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific) LAMEA (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players	Viatris Pharmaceuticals Ltd. (Mylan Laboratories India Pvt. Ltd.), Jubilant Life Sciences Ltd., Sun Pharmaceuticals Industries Ltd., Eva Pharma Pvt. Ltd., Zydus Cadila Healthcare Ltd., Cipla Ltd., Pfizer Ltd., Dr. Reddy’s Laboratories Ltd., Hetero Labs Pvt. Ltd., Gilead Sciences India Private Limited

CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
  - 1.4.1. Primary Research
  - 1.4.2. Secondary Research
  - 1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
- 3.1. Market Definition and Scope
- 3.2. Key Findings
  - 3.2.1. Top Investment Pockets
  - 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
  - 3.3.1. Bargaining Power of Suppliers
  - 3.3.2. Threat of New Entrants
  - 3.3.3. Threat of Substitutes
  - 3.3.4. Competitive Rivalry
  - 3.3.5. Bargaining Power among Buyers
- 3.5. Market Dynamics
  - 3.5.1. Drivers
  - 3.5.2. Restraints
  - 3.5.3. Opportunities
- 3.6. COVID-19 Impact Analysis
CHAPTER 4: REMDESIVIR MARKET, BY DOSAGE
- 4.1. Market Overview
  - 4.1.1 Market Size and Forecast, By Dosage
- 4.2. 2.5MG
  - 4.2.1. Key Market Trends, Growth Factors and Opportunities
  - 4.2.2. Market Size and Forecast, By Region
  - 4.2.3. Market Share Analysis, By Country
- 4.3. 5MG
  - 4.3.1. Key Market Trends, Growth Factors and Opportunities
  - 4.3.2. Market Size and Forecast, By Region
  - 4.3.3. Market Share Analysis, By Country
- 4.4. 100MG
  - 4.4.1. Key Market Trends, Growth Factors and Opportunities
  - 4.4.2. Market Size and Forecast, By Region
  - 4.4.3. Market Share Analysis, By Country
- 4.5. 200MG
  - 4.5.1. Key Market Trends, Growth Factors and Opportunities
  - 4.5.2. Market Size and Forecast, By Region
  - 4.5.3. Market Share Analysis, By Country
CHAPTER 5: REMDESIVIR MARKET, BY FORM
- 5.1. Market Overview
  - 5.1.1 Market Size and Forecast, By Form
- 5.2. Lyophilized Powder
  - 5.2.1. Key Market Trends, Growth Factors and Opportunities
  - 5.2.2. Market Size and Forecast, By Region
  - 5.2.3. Market Share Analysis, By Country
- 5.3. Concentrated Solution
  - 5.3.1. Key Market Trends, Growth Factors and Opportunities
  - 5.3.2. Market Size and Forecast, By Region
  - 5.3.3. Market Share Analysis, By Country
CHAPTER 6: REMDESIVIR MARKET, BY APPLICATION
- 6.1. Market Overview
  - 6.1.1 Market Size and Forecast, By Application
- 6.2. Ebola
  - 6.2.1. Key Market Trends, Growth Factors and Opportunities
  - 6.2.2. Market Size and Forecast, By Region
  - 6.2.3. Market Share Analysis, By Country
- 6.3. SARS-COV
  - 6.3.1. Key Market Trends, Growth Factors and Opportunities
  - 6.3.2. Market Size and Forecast, By Region
  - 6.3.3. Market Share Analysis, By Country
- 6.4. MERS-COV
  - 6.4.1. Key Market Trends, Growth Factors and Opportunities
  - 6.4.2. Market Size and Forecast, By Region
  - 6.4.3. Market Share Analysis, By Country
CHAPTER 7: REMDESIVIR MARKET, BY DISTRIBUTION CHANNEL
- 7.1. Market Overview
  - 7.1.1 Market Size and Forecast, By Distribution Channel
- 7.2. Hospital Pharmacy
  - 7.2.1. Key Market Trends, Growth Factors and Opportunities
  - 7.2.2. Market Size and Forecast, By Region
  - 7.2.3. Market Share Analysis, By Country
- 7.3. Retail Pharmacy
  - 7.3.1. Key Market Trends, Growth Factors and Opportunities
  - 7.3.2. Market Size and Forecast, By Region
  - 7.3.3. Market Share Analysis, By Country
- 7.4. Online Pharmacy
  - 7.4.1. Key Market Trends, Growth Factors and Opportunities
  - 7.4.2. Market Size and Forecast, By Region
  - 7.4.3. Market Share Analysis, By Country
CHAPTER 8: REMDESIVIR MARKET, BY REGION
- 8.1. Market Overview
  - 8.1.1 Market Size and Forecast, By Region
- 8.2. North America
  - 8.2.1. Key Market Trends and Opportunities
  - 8.2.2. Market Size and Forecast, By Dosage
  - 8.2.3. Market Size and Forecast, By Form
  - 8.2.4. Market Size and Forecast, By Application
  - 8.2.5. Market Size and Forecast, By Distribution Channel
  - 8.2.6. Market Size and Forecast, By Country
  - 8.2.7. U.S. Remdesivir Market
    - 8.2.7.1. Market Size and Forecast, By Dosage
    - 8.2.7.2. Market Size and Forecast, By Form
    - 8.2.7.3. Market Size and Forecast, By Application
    - 8.2.7.4. Market Size and Forecast, By Distribution Channel
  - 8.2.8. Canada Remdesivir Market
    - 8.2.8.1. Market Size and Forecast, By Dosage
    - 8.2.8.2. Market Size and Forecast, By Form
    - 8.2.8.3. Market Size and Forecast, By Application
    - 8.2.8.4. Market Size and Forecast, By Distribution Channel
  - 8.2.9. Mexico Remdesivir Market
    - 8.2.9.1. Market Size and Forecast, By Dosage
    - 8.2.9.2. Market Size and Forecast, By Form
    - 8.2.9.3. Market Size and Forecast, By Application
    - 8.2.9.4. Market Size and Forecast, By Distribution Channel
- 8.3. Europe
  - 8.3.1. Key Market Trends and Opportunities
  - 8.3.2. Market Size and Forecast, By Dosage
  - 8.3.3. Market Size and Forecast, By Form
  - 8.3.4. Market Size and Forecast, By Application
  - 8.3.5. Market Size and Forecast, By Distribution Channel
  - 8.3.6. Market Size and Forecast, By Country
  - 8.3.7. France Remdesivir Market
    - 8.3.7.1. Market Size and Forecast, By Dosage
    - 8.3.7.2. Market Size and Forecast, By Form
    - 8.3.7.3. Market Size and Forecast, By Application
    - 8.3.7.4. Market Size and Forecast, By Distribution Channel
  - 8.3.8. Germany Remdesivir Market
    - 8.3.8.1. Market Size and Forecast, By Dosage
    - 8.3.8.2. Market Size and Forecast, By Form
    - 8.3.8.3. Market Size and Forecast, By Application
    - 8.3.8.4. Market Size and Forecast, By Distribution Channel
  - 8.3.9. Italy Remdesivir Market
    - 8.3.9.1. Market Size and Forecast, By Dosage
    - 8.3.9.2. Market Size and Forecast, By Form
    - 8.3.9.3. Market Size and Forecast, By Application
    - 8.3.9.4. Market Size and Forecast, By Distribution Channel
  - 8.3.10. Spain Remdesivir Market
    - 8.3.10.1. Market Size and Forecast, By Dosage
    - 8.3.10.2. Market Size and Forecast, By Form
    - 8.3.10.3. Market Size and Forecast, By Application
    - 8.3.10.4. Market Size and Forecast, By Distribution Channel
  - 8.3.11. UK Remdesivir Market
    - 8.3.11.1. Market Size and Forecast, By Dosage
    - 8.3.11.2. Market Size and Forecast, By Form
    - 8.3.11.3. Market Size and Forecast, By Application
    - 8.3.11.4. Market Size and Forecast, By Distribution Channel
  - 8.3.12. Russia Remdesivir Market
    - 8.3.12.1. Market Size and Forecast, By Dosage
    - 8.3.12.2. Market Size and Forecast, By Form
    - 8.3.12.3. Market Size and Forecast, By Application
    - 8.3.12.4. Market Size and Forecast, By Distribution Channel
  - 8.3.13. Rest Of Europe Remdesivir Market
    - 8.3.13.1. Market Size and Forecast, By Dosage
    - 8.3.13.2. Market Size and Forecast, By Form
    - 8.3.13.3. Market Size and Forecast, By Application
    - 8.3.13.4. Market Size and Forecast, By Distribution Channel
- 8.4. Asia-Pacific
  - 8.4.1. Key Market Trends and Opportunities
  - 8.4.2. Market Size and Forecast, By Dosage
  - 8.4.3. Market Size and Forecast, By Form
  - 8.4.4. Market Size and Forecast, By Application
  - 8.4.5. Market Size and Forecast, By Distribution Channel
  - 8.4.6. Market Size and Forecast, By Country
  - 8.4.7. China Remdesivir Market
    - 8.4.7.1. Market Size and Forecast, By Dosage
    - 8.4.7.2. Market Size and Forecast, By Form
    - 8.4.7.3. Market Size and Forecast, By Application
    - 8.4.7.4. Market Size and Forecast, By Distribution Channel
  - 8.4.8. Japan Remdesivir Market
    - 8.4.8.1. Market Size and Forecast, By Dosage
    - 8.4.8.2. Market Size and Forecast, By Form
    - 8.4.8.3. Market Size and Forecast, By Application
    - 8.4.8.4. Market Size and Forecast, By Distribution Channel
  - 8.4.9. India Remdesivir Market
    - 8.4.9.1. Market Size and Forecast, By Dosage
    - 8.4.9.2. Market Size and Forecast, By Form
    - 8.4.9.3. Market Size and Forecast, By Application
    - 8.4.9.4. Market Size and Forecast, By Distribution Channel
  - 8.4.10. South Korea Remdesivir Market
    - 8.4.10.1. Market Size and Forecast, By Dosage
    - 8.4.10.2. Market Size and Forecast, By Form
    - 8.4.10.3. Market Size and Forecast, By Application
    - 8.4.10.4. Market Size and Forecast, By Distribution Channel
  - 8.4.11. Australia Remdesivir Market
    - 8.4.11.1. Market Size and Forecast, By Dosage
    - 8.4.11.2. Market Size and Forecast, By Form
    - 8.4.11.3. Market Size and Forecast, By Application
    - 8.4.11.4. Market Size and Forecast, By Distribution Channel
  - 8.4.12. Thailand Remdesivir Market
    - 8.4.12.1. Market Size and Forecast, By Dosage
    - 8.4.12.2. Market Size and Forecast, By Form
    - 8.4.12.3. Market Size and Forecast, By Application
    - 8.4.12.4. Market Size and Forecast, By Distribution Channel
  - 8.4.13. Malaysia Remdesivir Market
    - 8.4.13.1. Market Size and Forecast, By Dosage
    - 8.4.13.2. Market Size and Forecast, By Form
    - 8.4.13.3. Market Size and Forecast, By Application
    - 8.4.13.4. Market Size and Forecast, By Distribution Channel
  - 8.4.14. Indonesia Remdesivir Market
    - 8.4.14.1. Market Size and Forecast, By Dosage
    - 8.4.14.2. Market Size and Forecast, By Form
    - 8.4.14.3. Market Size and Forecast, By Application
    - 8.4.14.4. Market Size and Forecast, By Distribution Channel
  - 8.4.15. Rest of Asia Pacific Remdesivir Market
    - 8.4.15.1. Market Size and Forecast, By Dosage
    - 8.4.15.2. Market Size and Forecast, By Form
    - 8.4.15.3. Market Size and Forecast, By Application
    - 8.4.15.4. Market Size and Forecast, By Distribution Channel
- 8.5. LAMEA
  - 8.5.1. Key Market Trends and Opportunities
  - 8.5.2. Market Size and Forecast, By Dosage
  - 8.5.3. Market Size and Forecast, By Form
  - 8.5.4. Market Size and Forecast, By Application
  - 8.5.5. Market Size and Forecast, By Distribution Channel
  - 8.5.6. Market Size and Forecast, By Country
  - 8.5.7. Brazil Remdesivir Market
    - 8.5.7.1. Market Size and Forecast, By Dosage
    - 8.5.7.2. Market Size and Forecast, By Form
    - 8.5.7.3. Market Size and Forecast, By Application
    - 8.5.7.4. Market Size and Forecast, By Distribution Channel
  - 8.5.8. South Africa Remdesivir Market
    - 8.5.8.1. Market Size and Forecast, By Dosage
    - 8.5.8.2. Market Size and Forecast, By Form
    - 8.5.8.3. Market Size and Forecast, By Application
    - 8.5.8.4. Market Size and Forecast, By Distribution Channel
  - 8.5.9. Saudi Arabia Remdesivir Market
    - 8.5.9.1. Market Size and Forecast, By Dosage
    - 8.5.9.2. Market Size and Forecast, By Form
    - 8.5.9.3. Market Size and Forecast, By Application
    - 8.5.9.4. Market Size and Forecast, By Distribution Channel
  - 8.5.10. UAE Remdesivir Market
    - 8.5.10.1. Market Size and Forecast, By Dosage
    - 8.5.10.2. Market Size and Forecast, By Form
    - 8.5.10.3. Market Size and Forecast, By Application
    - 8.5.10.4. Market Size and Forecast, By Distribution Channel
  - 8.5.11. Argentina Remdesivir Market
    - 8.5.11.1. Market Size and Forecast, By Dosage
    - 8.5.11.2. Market Size and Forecast, By Form
    - 8.5.11.3. Market Size and Forecast, By Application
    - 8.5.11.4. Market Size and Forecast, By Distribution Channel
  - 8.5.12. Rest of LAMEA Remdesivir Market
    - 8.5.12.1. Market Size and Forecast, By Dosage
    - 8.5.12.2. Market Size and Forecast, By Form
    - 8.5.12.3. Market Size and Forecast, By Application
    - 8.5.12.4. Market Size and Forecast, By Distribution Channel
CHAPTER 9: COMPETITIVE LANDSCAPE
- 9.1. Introduction
- 9.2. Top Winning Strategies
- 9.3. Product Mapping Of Top 10 Player
- 9.4. Competitive Dashboard
- 9.5. Competitive Heatmap
- 9.6. Top Player Positioning,2022
CHAPTER 10: COMPANY PROFILES
- 10.1. Cipla Ltd.
  - 10.1.1. Company Overview
  - 10.1.2. Key Executives
  - 10.1.3. Company Snapshot
  - 10.1.4. Operating Business Segments
  - 10.1.5. Product Portfolio
  - 10.1.6. Business Performance
  - 10.1.7. Key Strategic Moves and Developments
- 10.2. Hetero Labs Pvt. Ltd.
  - 10.2.1. Company Overview
  - 10.2.2. Key Executives
  - 10.2.3. Company Snapshot
  - 10.2.4. Operating Business Segments
  - 10.2.5. Product Portfolio
  - 10.2.6. Business Performance
  - 10.2.7. Key Strategic Moves and Developments
- 10.3. Jubilant Life Sciences Ltd.
  - 10.3.1. Company Overview
  - 10.3.2. Key Executives
  - 10.3.3. Company Snapshot
  - 10.3.4. Operating Business Segments
  - 10.3.5. Product Portfolio
  - 10.3.6. Business Performance
  - 10.3.7. Key Strategic Moves and Developments
- 10.4. Viatris Pharmaceuticals Ltd. (Mylan Laboratories India Pvt. Ltd.)
  - 10.4.1. Company Overview
  - 10.4.2. Key Executives
  - 10.4.3. Company Snapshot
  - 10.4.4. Operating Business Segments
  - 10.4.5. Product Portfolio
  - 10.4.6. Business Performance
  - 10.4.7. Key Strategic Moves and Developments
- 10.5. Dr. Reddy’s Laboratories Ltd.
  - 10.5.1. Company Overview
  - 10.5.2. Key Executives
  - 10.5.3. Company Snapshot
  - 10.5.4. Operating Business Segments
  - 10.5.5. Product Portfolio
  - 10.5.6. Business Performance
  - 10.5.7. Key Strategic Moves and Developments
- 10.6. Sun Pharmaceuticals Industries Ltd.
  - 10.6.1. Company Overview
  - 10.6.2. Key Executives
  - 10.6.3. Company Snapshot
  - 10.6.4. Operating Business Segments
  - 10.6.5. Product Portfolio
  - 10.6.6. Business Performance
  - 10.6.7. Key Strategic Moves and Developments
- 10.7. Zydus Cadila Healthcare Ltd.
  - 10.7.1. Company Overview
  - 10.7.2. Key Executives
  - 10.7.3. Company Snapshot
  - 10.7.4. Operating Business Segments
  - 10.7.5. Product Portfolio
  - 10.7.6. Business Performance
  - 10.7.7. Key Strategic Moves and Developments
- 10.8. Pfizer Ltd.
  - 10.8.1. Company Overview
  - 10.8.2. Key Executives
  - 10.8.3. Company Snapshot
  - 10.8.4. Operating Business Segments
  - 10.8.5. Product Portfolio
  - 10.8.6. Business Performance
  - 10.8.7. Key Strategic Moves and Developments
- 10.9. Gilead Sciences India Private Limited
  - 10.9.1. Company Overview
  - 10.9.2. Key Executives
  - 10.9.3. Company Snapshot
  - 10.9.4. Operating Business Segments
  - 10.9.5. Product Portfolio
  - 10.9.6. Business Performance
  - 10.9.7. Key Strategic Moves and Developments
- 10.10. Eva Pharma Pvt. Ltd.
  - 10.10.1. Company Overview
  - 10.10.2. Key Executives
  - 10.10.3. Company Snapshot
  - 10.10.4. Operating Business Segments
  - 10.10.5. Product Portfolio
  - 10.10.6. Business Performance
  - 10.10.7. Key Strategic Moves and Developments

LIST OF TABLES
TABLE 1. GLOBAL REMDESIVIR MARKET, BY DOSAGE, 2022-2032 ($MILLION)
TABLE 2. GLOBAL REMDESIVIR MARKET FOR 2.5MG, BY REGION, 2022-2032 ($MILLION)
TABLE 3. GLOBAL REMDESIVIR MARKET FOR 5MG, BY REGION, 2022-2032 ($MILLION)
TABLE 4. GLOBAL REMDESIVIR MARKET FOR 100MG, BY REGION, 2022-2032 ($MILLION)
TABLE 5. GLOBAL REMDESIVIR MARKET FOR 200MG, BY REGION, 2022-2032 ($MILLION)
TABLE 6. GLOBAL REMDESIVIR MARKET, BY FORM, 2022-2032 ($MILLION)
TABLE 7. GLOBAL REMDESIVIR MARKET FOR LYOPHILIZED POWDER, BY REGION, 2022-2032 ($MILLION)
TABLE 8. GLOBAL REMDESIVIR MARKET FOR CONCENTRATED SOLUTION, BY REGION, 2022-2032 ($MILLION)
TABLE 9. GLOBAL REMDESIVIR MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 10. GLOBAL REMDESIVIR MARKET FOR EBOLA, BY REGION, 2022-2032 ($MILLION)
TABLE 11. GLOBAL REMDESIVIR MARKET FOR SARS-COV, BY REGION, 2022-2032 ($MILLION)
TABLE 12. GLOBAL REMDESIVIR MARKET FOR MERS-COV, BY REGION, 2022-2032 ($MILLION)
TABLE 13. GLOBAL REMDESIVIR MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 14. GLOBAL REMDESIVIR MARKET FOR HOSPITAL PHARMACY, BY REGION, 2022-2032 ($MILLION)
TABLE 15. GLOBAL REMDESIVIR MARKET FOR RETAIL PHARMACY, BY REGION, 2022-2032 ($MILLION)
TABLE 16. GLOBAL REMDESIVIR MARKET FOR ONLINE PHARMACY, BY REGION, 2022-2032 ($MILLION)
TABLE 17. GLOBAL REMDESIVIR MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 18. NORTH AMERICA REMDESIVIR, BY REGION, 2022-2032 ($MILLION)
TABLE 19. NORTH AMERICA REMDESIVIR, BY DOSAGE, 2022-2032 ($MILLION)
TABLE 20. NORTH AMERICA REMDESIVIR, BY FORM, 2022-2032 ($MILLION)
TABLE 21. NORTH AMERICA REMDESIVIR, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 22. NORTH AMERICA REMDESIVIR, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 23. U.S. REMDESIVIR, BY DOSAGE, 2022-2032 ($MILLION)
TABLE 24. U.S. REMDESIVIR, BY FORM, 2022-2032 ($MILLION)
TABLE 25. U.S. REMDESIVIR, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 26. U.S. REMDESIVIR, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 27. CANADA REMDESIVIR, BY DOSAGE, 2022-2032 ($MILLION)
TABLE 28. CANADA REMDESIVIR, BY FORM, 2022-2032 ($MILLION)
TABLE 29. CANADA REMDESIVIR, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 30. CANADA REMDESIVIR, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 31. MEXICO REMDESIVIR, BY DOSAGE, 2022-2032 ($MILLION)
TABLE 32. MEXICO REMDESIVIR, BY FORM, 2022-2032 ($MILLION)
TABLE 33. MEXICO REMDESIVIR, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 34. MEXICO REMDESIVIR, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 35. EUROPE REMDESIVIR, BY REGION, 2022-2032 ($MILLION)
TABLE 36. EUROPE REMDESIVIR, BY DOSAGE, 2022-2032 ($MILLION)
TABLE 37. EUROPE REMDESIVIR, BY FORM, 2022-2032 ($MILLION)
TABLE 38. EUROPE REMDESIVIR, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 39. EUROPE REMDESIVIR, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 40. FRANCE REMDESIVIR, BY DOSAGE, 2022-2032 ($MILLION)
TABLE 41. FRANCE REMDESIVIR, BY FORM, 2022-2032 ($MILLION)
TABLE 42. FRANCE REMDESIVIR, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 43. FRANCE REMDESIVIR, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 44. GERMANY REMDESIVIR, BY DOSAGE, 2022-2032 ($MILLION)
TABLE 45. GERMANY REMDESIVIR, BY FORM, 2022-2032 ($MILLION)
TABLE 46. GERMANY REMDESIVIR, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 47. GERMANY REMDESIVIR, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 48. ITALY REMDESIVIR, BY DOSAGE, 2022-2032 ($MILLION)
TABLE 49. ITALY REMDESIVIR, BY FORM, 2022-2032 ($MILLION)
TABLE 50. ITALY REMDESIVIR, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 51. ITALY REMDESIVIR, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 52. SPAIN REMDESIVIR, BY DOSAGE, 2022-2032 ($MILLION)
TABLE 53. SPAIN REMDESIVIR, BY FORM, 2022-2032 ($MILLION)
TABLE 54. SPAIN REMDESIVIR, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 55. SPAIN REMDESIVIR, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 56. UK REMDESIVIR, BY DOSAGE, 2022-2032 ($MILLION)
TABLE 57. UK REMDESIVIR, BY FORM, 2022-2032 ($MILLION)
TABLE 58. UK REMDESIVIR, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 59. UK REMDESIVIR, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 60. RUSSIA REMDESIVIR, BY DOSAGE, 2022-2032 ($MILLION)
TABLE 61. RUSSIA REMDESIVIR, BY FORM, 2022-2032 ($MILLION)
TABLE 62. RUSSIA REMDESIVIR, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 63. RUSSIA REMDESIVIR, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 64. REST OF EUROPE REMDESIVIR, BY DOSAGE, 2022-2032 ($MILLION)
TABLE 65. REST OF EUROPE REMDESIVIR, BY FORM, 2022-2032 ($MILLION)
TABLE 66. REST OF EUROPE REMDESIVIR, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 67. REST OF EUROPE REMDESIVIR, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 68. ASIA-PACIFIC REMDESIVIR, BY REGION, 2022-2032 ($MILLION)
TABLE 69. ASIA-PACIFIC REMDESIVIR, BY DOSAGE, 2022-2032 ($MILLION)
TABLE 70. ASIA-PACIFIC REMDESIVIR, BY FORM, 2022-2032 ($MILLION)
TABLE 71. ASIA-PACIFIC REMDESIVIR, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 72. ASIA-PACIFIC REMDESIVIR, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 73. CHINA REMDESIVIR, BY DOSAGE, 2022-2032 ($MILLION)
TABLE 74. CHINA REMDESIVIR, BY FORM, 2022-2032 ($MILLION)
TABLE 75. CHINA REMDESIVIR, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 76. CHINA REMDESIVIR, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 77. JAPAN REMDESIVIR, BY DOSAGE, 2022-2032 ($MILLION)
TABLE 78. JAPAN REMDESIVIR, BY FORM, 2022-2032 ($MILLION)
TABLE 79. JAPAN REMDESIVIR, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 80. JAPAN REMDESIVIR, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 81. INDIA REMDESIVIR, BY DOSAGE, 2022-2032 ($MILLION)
TABLE 82. INDIA REMDESIVIR, BY FORM, 2022-2032 ($MILLION)
TABLE 83. INDIA REMDESIVIR, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 84. INDIA REMDESIVIR, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 85. SOUTH KOREA REMDESIVIR, BY DOSAGE, 2022-2032 ($MILLION)
TABLE 86. SOUTH KOREA REMDESIVIR, BY FORM, 2022-2032 ($MILLION)
TABLE 87. SOUTH KOREA REMDESIVIR, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 88. SOUTH KOREA REMDESIVIR, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 89. AUSTRALIA REMDESIVIR, BY DOSAGE, 2022-2032 ($MILLION)
TABLE 90. AUSTRALIA REMDESIVIR, BY FORM, 2022-2032 ($MILLION)
TABLE 91. AUSTRALIA REMDESIVIR, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 92. AUSTRALIA REMDESIVIR, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 93. THAILAND REMDESIVIR, BY DOSAGE, 2022-2032 ($MILLION)
TABLE 94. THAILAND REMDESIVIR, BY FORM, 2022-2032 ($MILLION)
TABLE 95. THAILAND REMDESIVIR, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 96. THAILAND REMDESIVIR, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 97. MALAYSIA REMDESIVIR, BY DOSAGE, 2022-2032 ($MILLION)
TABLE 98. MALAYSIA REMDESIVIR, BY FORM, 2022-2032 ($MILLION)
TABLE 99. MALAYSIA REMDESIVIR, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 100. MALAYSIA REMDESIVIR, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 101. INDONESIA REMDESIVIR, BY DOSAGE, 2022-2032 ($MILLION)
TABLE 102. INDONESIA REMDESIVIR, BY FORM, 2022-2032 ($MILLION)
TABLE 103. INDONESIA REMDESIVIR, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 104. INDONESIA REMDESIVIR, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 105. REST OF ASIA PACIFIC REMDESIVIR, BY DOSAGE, 2022-2032 ($MILLION)
TABLE 106. REST OF ASIA PACIFIC REMDESIVIR, BY FORM, 2022-2032 ($MILLION)
TABLE 107. REST OF ASIA PACIFIC REMDESIVIR, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 108. REST OF ASIA PACIFIC REMDESIVIR, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 109. LAMEA REMDESIVIR, BY REGION, 2022-2032 ($MILLION)
TABLE 110. LAMEA REMDESIVIR, BY DOSAGE, 2022-2032 ($MILLION)
TABLE 111. LAMEA REMDESIVIR, BY FORM, 2022-2032 ($MILLION)
TABLE 112. LAMEA REMDESIVIR, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 113. LAMEA REMDESIVIR, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 114. BRAZIL REMDESIVIR, BY DOSAGE, 2022-2032 ($MILLION)
TABLE 115. BRAZIL REMDESIVIR, BY FORM, 2022-2032 ($MILLION)
TABLE 116. BRAZIL REMDESIVIR, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 117. BRAZIL REMDESIVIR, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 118. SOUTH AFRICA REMDESIVIR, BY DOSAGE, 2022-2032 ($MILLION)
TABLE 119. SOUTH AFRICA REMDESIVIR, BY FORM, 2022-2032 ($MILLION)
TABLE 120. SOUTH AFRICA REMDESIVIR, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 121. SOUTH AFRICA REMDESIVIR, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 122. SAUDI ARABIA REMDESIVIR, BY DOSAGE, 2022-2032 ($MILLION)
TABLE 123. SAUDI ARABIA REMDESIVIR, BY FORM, 2022-2032 ($MILLION)
TABLE 124. SAUDI ARABIA REMDESIVIR, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 125. SAUDI ARABIA REMDESIVIR, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 126. UAE REMDESIVIR, BY DOSAGE, 2022-2032 ($MILLION)
TABLE 127. UAE REMDESIVIR, BY FORM, 2022-2032 ($MILLION)
TABLE 128. UAE REMDESIVIR, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 129. UAE REMDESIVIR, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 130. ARGENTINA REMDESIVIR, BY DOSAGE, 2022-2032 ($MILLION)
TABLE 131. ARGENTINA REMDESIVIR, BY FORM, 2022-2032 ($MILLION)
TABLE 132. ARGENTINA REMDESIVIR, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 133. ARGENTINA REMDESIVIR, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 134. REST OF LAMEA REMDESIVIR, BY DOSAGE, 2022-2032 ($MILLION)
TABLE 135. REST OF LAMEA REMDESIVIR, BY FORM, 2022-2032 ($MILLION)
TABLE 136. REST OF LAMEA REMDESIVIR, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 137. REST OF LAMEA REMDESIVIR, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 138. CIPLA LTD.: KEY EXECUTIVES
TABLE 139. CIPLA LTD.: COMPANY SNAPSHOT
TABLE 140. CIPLA LTD.: OPERATING SEGMENTS
TABLE 141. CIPLA LTD.: PRODUCT PORTFOLIO
TABLE 142. CIPLA LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 143. HETERO LABS PVT. LTD.: KEY EXECUTIVES
TABLE 144. HETERO LABS PVT. LTD.: COMPANY SNAPSHOT
TABLE 145. HETERO LABS PVT. LTD.: OPERATING SEGMENTS
TABLE 146. HETERO LABS PVT. LTD.: PRODUCT PORTFOLIO
TABLE 147. HETERO LABS PVT. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 148. JUBILANT LIFE SCIENCES LTD.: KEY EXECUTIVES
TABLE 149. JUBILANT LIFE SCIENCES LTD.: COMPANY SNAPSHOT
TABLE 150. JUBILANT LIFE SCIENCES LTD.: OPERATING SEGMENTS
TABLE 151. JUBILANT LIFE SCIENCES LTD.: PRODUCT PORTFOLIO
TABLE 152. JUBILANT LIFE SCIENCES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 153. VIATRIS PHARMACEUTICALS LTD. (MYLAN LABORATORIES INDIA PVT. LTD.): KEY EXECUTIVES
TABLE 154. VIATRIS PHARMACEUTICALS LTD. (MYLAN LABORATORIES INDIA PVT. LTD.): COMPANY SNAPSHOT
TABLE 155. VIATRIS PHARMACEUTICALS LTD. (MYLAN LABORATORIES INDIA PVT. LTD.): OPERATING SEGMENTS
TABLE 156. VIATRIS PHARMACEUTICALS LTD. (MYLAN LABORATORIES INDIA PVT. LTD.): PRODUCT PORTFOLIO
TABLE 157. VIATRIS PHARMACEUTICALS LTD. (MYLAN LABORATORIES INDIA PVT. LTD.): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 158. DR. REDDY’S LABORATORIES LTD.: KEY EXECUTIVES
TABLE 159. DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT
TABLE 160. DR. REDDY’S LABORATORIES LTD.: OPERATING SEGMENTS
TABLE 161. DR. REDDY’S LABORATORIES LTD.: PRODUCT PORTFOLIO
TABLE 162. DR. REDDY’S LABORATORIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 163. SUN PHARMACEUTICALS INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 164. SUN PHARMACEUTICALS INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 165. SUN PHARMACEUTICALS INDUSTRIES LTD.: OPERATING SEGMENTS
TABLE 166. SUN PHARMACEUTICALS INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 167. SUN PHARMACEUTICALS INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 168. ZYDUS CADILA HEALTHCARE LTD.: KEY EXECUTIVES
TABLE 169. ZYDUS CADILA HEALTHCARE LTD.: COMPANY SNAPSHOT
TABLE 170. ZYDUS CADILA HEALTHCARE LTD.: OPERATING SEGMENTS
TABLE 171. ZYDUS CADILA HEALTHCARE LTD.: PRODUCT PORTFOLIO
TABLE 172. ZYDUS CADILA HEALTHCARE LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 173. PFIZER LTD.: KEY EXECUTIVES
TABLE 174. PFIZER LTD.: COMPANY SNAPSHOT
TABLE 175. PFIZER LTD.: OPERATING SEGMENTS
TABLE 176. PFIZER LTD.: PRODUCT PORTFOLIO
TABLE 177. PFIZER LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 178. GILEAD SCIENCES INDIA PRIVATE LIMITED: KEY EXECUTIVES
TABLE 179. GILEAD SCIENCES INDIA PRIVATE LIMITED: COMPANY SNAPSHOT
TABLE 180. GILEAD SCIENCES INDIA PRIVATE LIMITED: OPERATING SEGMENTS
TABLE 181. GILEAD SCIENCES INDIA PRIVATE LIMITED: PRODUCT PORTFOLIO
TABLE 182. GILEAD SCIENCES INDIA PRIVATE LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 183. EVA PHARMA PVT. LTD.: KEY EXECUTIVES
TABLE 184. EVA PHARMA PVT. LTD.: COMPANY SNAPSHOT
TABLE 185. EVA PHARMA PVT. LTD.: OPERATING SEGMENTS
TABLE 186. EVA PHARMA PVT. LTD.: PRODUCT PORTFOLIO
TABLE 187. EVA PHARMA PVT. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES
FIGURE 1. GLOBAL REMDESIVIR MARKET SEGMENTATION
FIGURE 2. GLOBAL REMDESIVIR MARKET
FIGURE 3. SEGMENTATION REMDESIVIR MARKET
FIGURE 4. TOP INVESTMENT POCKET IN REMDESIVIR MARKET
FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
FIGURE 8. LOW THREAT OF SUBSTITUTION
FIGURE 9. HIGH COMPETITIVE RIVALRY
FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALREMDESIVIR MARKET
FIGURE 11. REMDESIVIR MARKET SEGMENTATION, BY BY DOSAGE
FIGURE 12. REMDESIVIR MARKET FOR 2.5MG, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 13. REMDESIVIR MARKET FOR 5MG, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 14. REMDESIVIR MARKET FOR 100MG, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 15. REMDESIVIR MARKET FOR 200MG, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 16. REMDESIVIR MARKET SEGMENTATION, BY BY FORM
FIGURE 17. REMDESIVIR MARKET FOR LYOPHILIZED POWDER, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 18. REMDESIVIR MARKET FOR CONCENTRATED SOLUTION, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 19. REMDESIVIR MARKET SEGMENTATION, BY BY APPLICATION
FIGURE 20. REMDESIVIR MARKET FOR EBOLA, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 21. REMDESIVIR MARKET FOR SARS-COV, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 22. REMDESIVIR MARKET FOR MERS-COV, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 23. REMDESIVIR MARKET SEGMENTATION, BY BY DISTRIBUTION CHANNEL
FIGURE 24. REMDESIVIR MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 25. REMDESIVIR MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 26. REMDESIVIR MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 27. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
FIGURE 28. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
FIGURE 29. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
FIGURE 30. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 31. COMPETITIVE DASHBOARD
FIGURE 32. COMPETITIVE HEATMAP: REMDESIVIR MARKET
FIGURE 33. Top player positioning, 2022
FIGURE 34. CIPLA LTD.: NET SALES, 2020-2022 ($MILLION)
FIGURE 35. CIPLA LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 36. CIPLA LTD.: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 37. HETERO LABS PVT. LTD.: NET SALES, 2020-2022 ($MILLION)
FIGURE 38. HETERO LABS PVT. LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 39. HETERO LABS PVT. LTD.: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 40. JUBILANT LIFE SCIENCES LTD.: NET SALES, 2020-2022 ($MILLION)
FIGURE 41. JUBILANT LIFE SCIENCES LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 42. JUBILANT LIFE SCIENCES LTD.: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 43. VIATRIS PHARMACEUTICALS LTD. (MYLAN LABORATORIES INDIA PVT. LTD.): NET SALES, 2020-2022 ($MILLION)
FIGURE 44. VIATRIS PHARMACEUTICALS LTD. (MYLAN LABORATORIES INDIA PVT. LTD.): REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 45. VIATRIS PHARMACEUTICALS LTD. (MYLAN LABORATORIES INDIA PVT. LTD.): REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 46. DR. REDDY’S LABORATORIES LTD.: NET SALES, 2020-2022 ($MILLION)
FIGURE 47. DR. REDDY’S LABORATORIES LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 48. DR. REDDY’S LABORATORIES LTD.: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 49. SUN PHARMACEUTICALS INDUSTRIES LTD.: NET SALES, 2020-2022 ($MILLION)
FIGURE 50. SUN PHARMACEUTICALS INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 51. SUN PHARMACEUTICALS INDUSTRIES LTD.: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 52. ZYDUS CADILA HEALTHCARE LTD.: NET SALES, 2020-2022 ($MILLION)
FIGURE 53. ZYDUS CADILA HEALTHCARE LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 54. ZYDUS CADILA HEALTHCARE LTD.: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 55. PFIZER LTD.: NET SALES, 2020-2022 ($MILLION)
FIGURE 56. PFIZER LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 57. PFIZER LTD.: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 58. GILEAD SCIENCES INDIA PRIVATE LIMITED: NET SALES, 2020-2022 ($MILLION)
FIGURE 59. GILEAD SCIENCES INDIA PRIVATE LIMITED: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 60. GILEAD SCIENCES INDIA PRIVATE LIMITED: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 61. EVA PHARMA PVT. LTD.: NET SALES, 2020-2022 ($MILLION)
FIGURE 62. EVA PHARMA PVT. LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 63. EVA PHARMA PVT. LTD.: REVENUE SHARE, BY REGION, 2032 (%)

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

U.S.-Canada Toll-free: +1-800-792-5285
Int'l :	+1-503-894-6022
Europe :	+44-845-528-1300
Email :	help@alliedmarketresearch.com

Life Sciences	Construction & Manufacturing	Semiconductor & Electronics
Consumer Goods	Food & Beverages	Automotive & Tarnsportation
Materials & Chemicals	Energy & Power	ICT & Media
Aerospace & Defense	BFSI
You must check at least one industry.

Your Shopping Cart Is Empty

Continue Shopping

Remdesivir Market Global Opportunity Analysis and Industry Forecast, 2023-2032

2023

Remdesivir Market

Remdesivir Market

by Dosage (2.5MG, 5MG, 100MG, 200MG), by Form (Lyophilized Powder, Concentrated Solution), by Application (Ebola, SARS-COV, MERS-COV) and by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2023-2032

COVID-19

CHAPTER 1: INTRODUCTION

1.1. Report Description

1.2. Key Market Segments

1.3. Key Benefits

1.4. Research Methodology

1.4.1. Primary Research

1.4.2. Secondary Research

1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

3.1. Market Definition and Scope

3.2. Key Findings

3.2.1. Top Investment Pockets

3.2.2. Top Winning Strategies

3.3. Porter's Five Forces Analysis

3.3.1. Bargaining Power of Suppliers

3.3.2. Threat of New Entrants

3.3.3. Threat of Substitutes

3.3.4. Competitive Rivalry

3.3.5. Bargaining Power among Buyers

3.5. Market Dynamics

3.5.1. Drivers

3.5.2. Restraints

3.5.3. Opportunities

3.6. COVID-19 Impact Analysis

CHAPTER 4: REMDESIVIR MARKET, BY DOSAGE

4.1. Market Overview

4.1.1 Market Size and Forecast, By Dosage

4.2. 2.5MG

4.2.1. Key Market Trends, Growth Factors and Opportunities

4.2.2. Market Size and Forecast, By Region

4.2.3. Market Share Analysis, By Country

4.3. 5MG

4.3.1. Key Market Trends, Growth Factors and Opportunities

4.3.2. Market Size and Forecast, By Region

4.3.3. Market Share Analysis, By Country

4.4. 100MG

4.4.1. Key Market Trends, Growth Factors and Opportunities

4.4.2. Market Size and Forecast, By Region

4.4.3. Market Share Analysis, By Country

4.5. 200MG

4.5.1. Key Market Trends, Growth Factors and Opportunities

4.5.2. Market Size and Forecast, By Region

4.5.3. Market Share Analysis, By Country

CHAPTER 5: REMDESIVIR MARKET, BY FORM

5.1. Market Overview

5.1.1 Market Size and Forecast, By Form

5.2. Lyophilized Powder

5.2.1. Key Market Trends, Growth Factors and Opportunities

5.2.2. Market Size and Forecast, By Region

5.2.3. Market Share Analysis, By Country

5.3. Concentrated Solution

5.3.1. Key Market Trends, Growth Factors and Opportunities

5.3.2. Market Size and Forecast, By Region

5.3.3. Market Share Analysis, By Country

CHAPTER 6: REMDESIVIR MARKET, BY APPLICATION

6.1. Market Overview

6.1.1 Market Size and Forecast, By Application

6.2. Ebola

6.2.1. Key Market Trends, Growth Factors and Opportunities

6.2.2. Market Size and Forecast, By Region

6.2.3. Market Share Analysis, By Country

6.3. SARS-COV

6.3.1. Key Market Trends, Growth Factors and Opportunities

6.3.2. Market Size and Forecast, By Region

6.3.3. Market Share Analysis, By Country

6.4. MERS-COV

6.4.1. Key Market Trends, Growth Factors and Opportunities

6.4.2. Market Size and Forecast, By Region

6.4.3. Market Share Analysis, By Country

CHAPTER 7: REMDESIVIR MARKET, BY DISTRIBUTION CHANNEL

Remdesivir Market
Global Opportunity Analysis and Industry Forecast, 2023-2032